Fig. 6.

Tissue distribution and in vivo effect of MitoGamide in mice. a–c MitoGamide level was measured in tissues, heart, kidney and liver, collected 4-h post i.v. injection (100-nmol/mouse, or equivalent to 2 mg/kg for mice weighing 25–30 g) from both wild-type and Akita mice (n = 5). The difference between wild-type and Akita groups has been tested with Student’s t test. d–f MitoGamide (10 mg/kg, approximately 500 nmol/mouse) was given to mice by oral gavage; then its contents in heart, liver and kidney were measured by LC-MS/MS (n = 3). Values are mean ± SEM. Effect of MitoGamide on heart function. g The effect of 12 week long MitoGamide treatment (10 mg/kg daily oral gavage) on E/A ratio, accessed by echocardiography (n = 11–15). h Representative Western blot and the quantification of LC3II expression normalized by LC3I in mitochondrial fractions of heart tissues collected after the 12 weeks treatment (n = 3–6). Values are mean ± SEM. Statistical significance has been tested by One-way ANOVA